The April 2026 final order under Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing targeted tax relief and research access while leaving recreational and unlicensed forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29 and concluded by July 15, 2026, with post-hearing briefs filed in August showing the DEA arguing that marijuana no longer meets Schedule I criteria based on HHS and FDA medical-use findings. The administrative law judge recommendation remains pending amid mostly opposing hearing participants and ongoing D.C. Circuit challenges. Trader pricing reflects the narrow April action and procedural timeline as the dominant constraints on full rescheduling by year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$802,588 Vol.
31 dic 2026
30 de septiembre
2%
31 de diciembre
26%
$802,588 Vol.
30 de septiembre
$262 Vol.
2%
31 de diciembre
$192,755 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order under Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing targeted tax relief and research access while leaving recreational and unlicensed forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29 and concluded by July 15, 2026, with post-hearing briefs filed in August showing the DEA arguing that marijuana no longer meets Schedule I criteria based on HHS and FDA medical-use findings. The administrative law judge recommendation remains pending amid mostly opposing hearing participants and ongoing D.C. Circuit challenges. Trader pricing reflects the narrow April action and procedural timeline as the dominant constraints on full rescheduling by year-end.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Feb 7, 2026, 5:04 PM ET
Volumen
$802,588Fecha de finalización
1 ene 2027Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 final order under Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing targeted tax relief and research access while leaving recreational and unlicensed forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29 and concluded by July 15, 2026, with post-hearing briefs filed in August showing the DEA arguing that marijuana no longer meets Schedule I criteria based on HHS and FDA medical-use findings. The administrative law judge recommendation remains pending amid mostly opposing hearing participants and ongoing D.C. Circuit challenges. Trader pricing reflects the narrow April action and procedural timeline as the dominant constraints on full rescheduling by year-end.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$802,588Fecha de finalización
1 ene 2027Mercado abierto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 final order under Acting Attorney General Todd Blanche immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, providing targeted tax relief and research access while leaving recreational and unlicensed forms in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling from Schedule I to III began June 29 and concluded by July 15, 2026, with post-hearing briefs filed in August showing the DEA arguing that marijuana no longer meets Schedule I criteria based on HHS and FDA medical-use findings. The administrative law judge recommendation remains pending amid mostly opposing hearing participants and ongoing D.C. Circuit challenges. Trader pricing reflects the narrow April action and procedural timeline as the dominant constraints on full rescheduling by year-end.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes